Healthy Returns: A key step forward for Novo Nordisk's GLP-1 pill

Novo Nordisk's oral semaglutide (Rybelsus) received FDA approval to reduce major cardiovascular risks in type 2 diabetes patients, further validating the broad health benefits of GLP-1s. This approval sets the stage for an anticipated FDA decision on oral semaglutide for obesity, where it is poised to compete with Eli Lilly's orforglipron for market share in the expanding GLP-1 pill segment. Separately, Novo Nordisk is actively discussing drug pricing for its blockbuster GLP-1 injectables, Ozempic and Wegovy, with the Trump administration, while also ramping up manufacturing to meet surging demand.

Analysis

Novo Nordisk's oral semaglutide (Rybelsus) secured FDA approval for reducing major cardiovascular events, including heart attack, stroke, and cardiovascular death, in high-risk type 2 diabetes patients. This approval, based on a 14% risk reduction over four years in the SOUL trial, underscores the expanding therapeutic utility of GLP-1s beyond glycemic control and weight management. This further solidifies the drug's market position and broadens its addressable patient population.

The market is keenly awaiting an FDA decision on oral semaglutide for obesity, which would position it as the first GLP-1 pill for this indication. This move sets up a direct competitive dynamic with Eli Lilly's orforglipron, expected to launch next year. While Novo Nordisk's oral semaglutide showed slightly higher efficacy in obesity trials, Eli Lilly's small-molecule orforglipron offers potential advantages in easier absorption, no dietary restrictions, and scalable manufacturing.

Concurrently, Novo Nordisk is engaged in active discussions with the Trump administration regarding "most favored nation pricing" for its blockbuster GLP-1 injectables, Ozempic and Wegovy, with a stated goal of reducing Ozempic's cash price to $150. This regulatory pressure coincides with Novo Nordisk's strategic ramp-up of manufacturing facilities in North Carolina, aimed at ensuring supply readiness for anticipated demand, particularly for its oral semaglutide's potential obesity indication. The company's Novocare direct-to-consumer platform, currently accounting for 11% of Wegovy sales, could also be integrated into a "TrumpRx" initiative.

Key Decisions for Investors

• Monitor Novo Nordisk's (NVO) oral semaglutide (Rybelsus) sales trajectory following its expanded cardiovascular risk reduction indication, as this broadens its market and reinforces GLP-1 efficacy.
• Evaluate the competitive implications of the upcoming FDA decision for NVO's oral semaglutide in obesity against Eli Lilly's (LLY) orforglipron, considering their differing efficacy, manufacturing scalability, and patient convenience profiles.
• Assess the potential impact of ongoing drug pricing negotiations with the Trump administration on Novo Nordisk's (NVO) Ozempic and Wegovy revenue streams, particularly regarding cash price reductions and direct-to-consumer channel integration.
• Observe Novo Nordisk's (NVO) manufacturing capacity expansion, as successful scaling will be critical for meeting anticipated demand for its oral GLP-1 products and mitigating supply chain risks.